🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

Recruitingn/aAges any - anyFemaleFu Xing Hospital, Capital Medical University
NCT06862089 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV). The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Recent history of miscarriage or delivery (within the past 8 weeks) * Strong willingness to undergo conservative management * Hemodynamically stable * Signed informed consent form Exclusion Criteria: * Heavy vaginal bleeding (requiring immediate surgical intervention) * Active pelvic or systemic infection (e.g., fever \>38°C, elevated CRP/WBC) * Severe dysfunction of vital organs (heart, liver, or kidney) * Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance) * Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels) * Placenta accreta spectrum disorders diagnosed during current pregnancy * History of uterine artery embolization
💊

What it tests

  • Not listed
📍

Where

1 site
Hysteroscopy Center, Fuxing Hospital, Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy